Bioregulators & Organ Support

Epithalon (Epitalon)

Protocol not independently verified FDA safety flag Longevity Circadian

Educational reference only. Read the full disclaimer. The protocols below are not automatically an FDA-approved or clinically verified regimen unless explicitly marked as label-verified or human-trial protocol above.

Synthetic AEDG and pineal-peptide research.

Research Summary

Evidence: Limited direct human AEDG evidence
Primary research: Direct synthetic-AEDG research must be separated from Epithalamin studies.
Research focus: Synthetic AEDG and pineal-peptide research.
Mechanism: A synthetic tetrapeptide: alanine, glutamic acid, aspartic acid, glycine.
Evidence limits: Human Epithalamin findings do not establish synthetic Epitalon effects or high-dose regimens.

IdentityEpitalon / Epithalon is AEDG; Epithalamin is a different preparation.

Target / actionA synthetic tetrapeptide: alanine, glutamic acid, aspartic acid, glycine.

Route contextInterpret only the route used in the cited AEDG study.

Dose contextDirectly studied AEDG dosing is separate from equal-total-dose extrapolations.

Evidence limitHuman Epithalamin findings do not establish synthetic Epitalon effects or high-dose regimens.

What Epitalon is

Epitalon, also spelled Epithalon, is a synthetic tetrapeptide made of four amino acids: alanine, glutamic acid, aspartic acid and glycine (Ala-Glu-Asp-Gly, commonly abbreviated AEDG).

Epitalon emerged from a broader research programme involving Epithalamin, a peptide preparation derived from animal pineal tissue. The two are historically connected and have similar names, but they are different substances and their evidence cannot be treated as interchangeable.

Why Epithalamin and Epitalon are commonly confused

Substance	What it is
Epitalon / Epithalon	A defined synthetic four-amino-acid peptide: AEDG.
Epithalamin	A complex pineal-gland peptide preparation containing multiple peptides.

Many claims described online as “human Epitalon research” trace back to studies that used Epithalamin. Those studies remain relevant to the history of pineal-peptide research, but they are not direct human studies of synthetic AEDG Epitalon. The FDA's 2026 scientific evaluation also distinguishes synthetic Epitalon from the Epithalamin pineal-polypeptide preparation [1].

A dose, route, cycle or outcome reported for Epithalamin cannot automatically be applied to Epitalon.
Findings involving longevity, mortality, melatonin, treatment cycles or safety only describe the substance that was actually administered.
When an Epithalamin study is presented as an Epitalon study, the evidence has already been misclassified before dosing is considered.

Dosing evidence

High-dose community protocols. High-dose Epitalon protocols are widely circulated online and are sometimes presented as though they are supported by human Epitalon research. The Russian and Ukrainian human studies commonly cited in support of these regimens used Epithalamin, a different pineal peptide preparation, and did not administer synthetic Epitalon (AEDG) [3]. Human evidence does not establish 5 to 10 mg/day as a validated Epitalon dose.

Dose at a glance

Regimen	Route	Course	Evidence status
0.5 mg/day for 20 days	Sublingual	10 mg total	The regimen directly documented in controlled human AEDG research: the circadian and melatonin-biomarker study [2].
1 mg/day for 10 days	Not separately studied	10 mg total	Delivers the same 10 mg cumulative amount over a shorter period. This shorter schedule was not separately tested in the cited human study.
5 to 10 mg/day for roughly 10 to 20 days	Subcutaneous (community)	Varies	A community protocol widely repeated online. It has not been validated: controlled human AEDG research has not established it, and much of the human evidence cited for it used Epithalamin.

What was directly studied in humans

The controlled human study involved 75 women aged 40 to 50, primarily night-shift workers. Forty participants with reduced urinary 6-sulfatoxymelatonin were divided into placebo and sublingual AEDG groups. The AEDG group received 0.5 mg/day for 20 days [2].

Urinary 6-sulfatoxymelatonin increased.
Changes in clock-gene expression were reported.
The study also reported broadly described subjective changes in physical and psycho-emotional condition.

What the study did not establish

It did not establish a subcutaneous or injectable Epitalon dose.
It was not designed as an insomnia-treatment trial.
It did not directly establish improvements in sleep duration, sleep efficiency, sleep latency, sleep architecture or insomnia severity.
It did not establish clinical anti-aging efficacy or a human longevity benefit.

Route matters. The controlled human AEDG study used sublingual administration. It therefore does not establish that the same dose is validated when Epitalon is given by subcutaneous injection.

Why 5 to 10 mg/day is commonly seen online

As the names Epithalamin and Epitalon became conflated in secondary sources, Epithalamin findings were increasingly described as “Epitalon research.” Forums, vendors and protocol pages then repeated the same claim, creating the appearance of broad agreement even though the evidence trail often leads back to studies that did not administer Epitalon.

Russian and Ukrainian studies used Epithalamin. The cited human studies used a complex pineal preparation, not synthetic AEDG Epitalon.
The names became conflated. Secondary sources increasingly described Epithalamin research as “Epitalon research.”
The claim was repeated. Forums, vendors and protocol pages copied the same interpretation.
Repetition resembled validation. Several apparent sources may ultimately trace back to the same misidentified evidence.
Animal studies were added later. Microgram animal data became a second rationale for multi-milligram human protocols.

How animal-to-human dose translation works

Animal studies can help researchers understand Epitalon biology and estimate exposure ranges for future human research. They do not, by themselves, establish an effective or appropriate human dose.

Approach	What it involves
Incorrect approach	Take a rat or mouse dose and simply multiply it by human body weight.
Typical research approach	Normalise the animal exposure relative to body size, then use an appropriate interspecies method such as body-surface-area scaling to estimate a human-equivalent exposure.
What the estimate cannot establish	The result remains a research estimate. It does not establish efficacy, safety, injection frequency, route or cycle length in humans.

Why the animal data do not establish 5 to 10 mg/day

The animal exposures are small and measured in micrograms [4]:

Species	Dose	Route
Rat	1 µg per rat	Subcutaneous
Mouse	1 µg/day per mouse	Subcutaneous
Rhesus monkey	2 µg/kg/day	Intramuscular

Begin with the actual animal exposure. A fixed dose such as 1 µg per rat is not the same as a weight-based dose expressed in mg/kg.
To compare exposure across species, the animal dose must first be normalised relative to body size.
Researchers may then use an interspecies method such as body-surface-area scaling to estimate a human-equivalent dose. That result is a translational estimate used to guide further study, and it does not prove a human dose.
The estimate still requires human testing. Dose-ranging, safety, pharmacokinetic and efficacy data are needed before a human regimen can be considered established.

A calculated human-equivalent dose is not automatically “the human dose.” It is an estimate used to help design the next stage of research. For context, 5 mg equals 5,000 µg and 10 mg equals 10,000 µg. Raw doses cannot be compared directly across species, but the scale difference shows why a 5 to 10 mg/day human protocol does not follow automatically from these animal studies. Additional assumptions are required, and those assumptions cannot substitute for human dose-finding research.

Two distinct evidence errors

Error	What happens
Identity error: Epithalamin to Epitalon	A study administers a complex pineal preparation, but later sources describe it as though participants received synthetic AEDG.
Translation error: animal Epitalon to a human multi-milligram protocol	A microgram-scale animal exposure is extrapolated and then presented as if it clinically validated a human regimen.

Evidence at a glance

Evidence type	Strength
Direct human AEDG	Very limited. The directly documented regimen is 0.5 mg/day sublingually for 20 days. A 1 mg/day for 10 days schedule provides the same 10 mg cumulative amount but was not separately tested in that human study.
Human injectable AEDG	Extremely limited. The sublingual study does not establish an injectable dose.
Human Epithalamin	Considerably more historical human research exists, but it involves a different preparation and cannot be treated as direct Epitalon evidence.
Animal Epitalon	Meaningful but limited. Published examples include microgram-scale subcutaneous and intramuscular exposures.
Cell and mechanism research	Useful for biological plausibility and mechanism, but it cannot establish a human treatment protocol.
Human longevity	Not established for synthetic Epitalon.
Human telomere effects	Not established in living humans.
FDA approval	No. Epitalon is not an FDA-approved drug.

Key takeaways

What Epitalon is: the synthetic AEDG tetrapeptide. It is historically connected to Epithalamin research, but it is a different substance.
Human dose evidence: the clearest directly documented human AEDG regimen is 0.5 mg/day sublingually for 20 days, totalling 10 mg. A 1 mg/day for 10 days schedule provides the same cumulative 10 mg but was not separately established in the cited human study.
Why higher doses appear online: a 5 to 10 mg/day regimen for 10 to 20 days is commonly repeated online. A major source of the confusion is that Russian and Ukrainian Epithalamin studies were later described as though they were Epitalon studies, allowing a misclassified evidence trail to spread across community sources.
What the animal studies show: microgram-scale animal studies can inform future research, but animal-to-human scaling produces only an estimated human-equivalent exposure. It does not establish efficacy, the optimal dose, route, frequency or cycle duration in humans.

Sources

U.S. Food and Drug Administration. 2026 scientific evaluation of Epitalon. Distinguishes synthetic Epitalon (AEDG) from the Epithalamin pineal-polypeptide preparation.
Controlled human study of sublingual AEDG: 75 women aged 40 to 50, primarily night-shift workers; 40 participants with reduced urinary 6-sulfatoxymelatonin divided into placebo and AEDG 0.5 mg/day for 20 days. Urinary 6-sulfatoxymelatonin and clock-gene expression outcomes.
Russian and Ukrainian human studies of Epithalamin, a complex pineal peptide preparation. Historical pineal-peptide research; these studies did not administer synthetic Epitalon.
Animal Epitalon studies with microgram-scale exposures: 1 µg per rat SC, 1 µg/day per mouse SC, and 2 µg/kg/day IM in rhesus monkeys.